ReviewMicrobial biotechnology2025
Attenuated Strains of Pseudomonas aeruginosa: A Promising Cell Factory for Rhamnolipid Production.
Review in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Engineering growth independent production: programmable control loops for high-titer rhamnolipids for improved green surfactant sustainability.Bioprocess and biosystems engineering · 2026Review
- Attenuated Strains of Pseudomonas aeruginosa: A Promising Cell Factory for Rhamnolipid Production.Microbial biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Biodegradable compounds like rhamnolipids provide an environmentally friendly alternative to petroleum-based surfactants. Pseudomonas aeruginosa is the most proficient producer of rhamnolipids. The genetic plasticity and metabolic versatility of P. aeruginosa can be harnessed to leverage the production of rhamnolipids. However, P. aeruginosa carries virulence factors and can cause debilitating diseases in immunocompromised individuals. Bacteria other than P. aeruginosa have been used as heterologous hosts for rhamnolipid production through genetic engineering. Our lab had previously developed genetically attenuated strains of P. aeruginosa to produce polysaccharide alginate. These strains can also be used for rhamnolipid production. This review examines the unique genetic, biochemical, and physiological characteristics of P. aeruginosa amenable to be exploited via bioengineering and the existing models for rhamnolipid production. Further, we propose the attenuated strains of P. aeruginosa as a safe cell-factory for industrial production and biomedical use of rhamnolipids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.